Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 02 - 24 tags : Trial save search
Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Published: 2022-02-24 (Crawled : 23:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 0.71%
H: 13.92%
C: 13.8%
pln-7480 phase 2 fibrosis trial therapeutics positive enroll phase 2b
Univar Solutions Names Michael DelliCompagni Vice President of Global Industrial Solutions
Published: 2022-02-24 (Crawled : 22:00) - prnewswire.com
UNVR | $36.14 0.47% 0.0% 0
|
Distribution Services
|
| O: 3.84%
H: 4.31%
C: 3.25%
trial solutions
Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome
Published: 2022-02-24 (Crawled : 20:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -4.06%
H: 0.0%
C: 0.0%
RGLS | $2.23 -1.33% -1.35% 92K
|
Health Technology
|
| O: -3.66%
H: 8.0%
C: 6.5%
phase 2 trial therapeutics syndros enroll
New Study from StrategyR Highlights a $9.2 Billion Global Market for Industrial Furnaces and Ovens by 2026
Published: 2022-02-24 (Crawled : 17:00) - prnewswire.com
ADRZY | News | $11.875 -17.72% 380
|
Manufacturing
| Email alert
Add to watchlist
ADRZF | News | $58.8 -0.83% 1.5K
|
Producer Manufacturing
| Email alert
Add to watchlist
ces trial
Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
Published: 2022-02-24 (Crawled : 14:30) - globenewswire.com
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: 0.0%
H: 9.0%
C: 9.0%
ad04 alcohol use disorder treatment als order trial phase 3
Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
Published: 2022-02-24 (Crawled : 13:00) - biospace.com/
TRVI | $2.68 -5.97% -6.34% 120K
|
Health Technology
|
| O: 8.7%
H: 28.6%
C: -2.0%
treatment fibrosis trial therapeutics report chronic cough
Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer
Published: 2022-02-24 (Crawled : 06:00) - prnewswire.com
GTHX | $3.98 -5.01% -5.28% 340K
|
Health Technology
|
| O: -12.4%
H: 28.19%
C: 28.19%
chinese trilaciclib trial cel lung cancer cancer
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-02-24 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -1.25%
H: 1.21%
C: 1.04%
cd73 trial phase 1 antibody phase 1b
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.